http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102272947-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8813 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5038 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48 |
| filingDate | 2019-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102272947-B1 |
| titleOfInvention | Method, composition and kit for screening fatty acid synthase inhibitor |
| abstract | Disclosed herein are methods, compositions and kits for the screening of fatty acid synthase inhibitors. In one aspect, quantitative and qualitative analysis is possible at the same time, and it is possible to screen for a large amount of candidate substances more quickly compared to the existing molecular biological experiments, and N1-acetylspermidine, spermidine, spermine, L-tryptophan , 8,11,14-eicosatrienoic acid, docosapentaenoic acid, lysoPC (16:1), lysoPC (20:2), lysoPC (18:0), lysoPC (20:1) , lysoPC (p-16:0), palmitoyl-L-carnitine, PC (19:1), PC (35:4), PE (18:1), PE (34:1), PE (37: 6), prostaglandin A2, a fatty acid synthase inhibitor using at least one selected from the group consisting of stearic acid and vaccenic acid to determine whether a fatty acid synthase inhibitor candidate exhibits a significant expression change in a cell line The screening efficiency for Accordingly, the present invention has the advantage that it can be used in various ways in the development of new drugs showing the effect of inhibiting fatty acid synthase. |
| priorityDate | 2019-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.